Infected Blood Inquiry

Read the latest news on the Public
Inquiry into Contaminated Blood

The taintedblood Timeline  -  what really happened...

"To no one will we sell, to no one deny or delay, right or justice."
Magna Carta - 15th June, 1215

 
No of entries selected: 12 of 711
1985
October
The Lancet - Misleading Article Catastrophically Misrepresenting Safety
Dr John Petricciani, the director of the Division of Blood and Blood Products of the FDA, writes in The Lancet that:
"Infectious LAV/HTLV-III [HIV] is unlikely to be present in currently licensed heat-treated factor concentrates, and that the use of such factor concentrates should not result in additional cases of AIDS in persons with hemophilia."

Note: See the Find Related Entries link below to learn why this article was so misleading.

Source: Krever Commission Report (1997), Vol 3, Part IV, Chap. 27, page 756.
Type: Article
Location: USA
Find related entries
1985
October
Armour - Third Case of Seroconversion in a Haemophiliac
A 3rd case of seroconversion in an haemophiliac is associated with the use of Armour's H.T. Factorate.
Source: Krever Commission Report (1997) Vol 3, Part IV, Chap. 33, page 933.
Type: Development
Location: USA
Find related entries
1985
24 October
Sir Donald Acheson CMO - Draft Speech to PHLS on AIDS
In the final draft of a speech by the then CMO, Sir Donald Acheson to the PHLS in October 1985, we discover a certain overconfidence regarding his belief that no new cases of AIDS infection should occur in the future in the haemophiliac group...

Sir Donald Acheson, October 1985: "These data show that HTLV3 infection:

  1. has increased in prevalence among homosexuals in London. Elsewhere it may also be increasing in prevalence but remains less common that [than?] in the capital;

  2. It is prevalent among haemophiliacs, particularly sufferers from Type 'A' haemophilia. Fortunately however no new cases of infection should now occur in this group;

  3. it has appeared, so far at low prevalence among female partners of haemophiliacs;

  4. it remains relatively uncommon among drug abusers."

NOTE: We must point out that the CMO's comment was somewhat overconfident since that very same month, there was the third is a spate of cases of seroconversion in UK haemophiliacs associated with the use of an imported commercial concentrate; Armour's H.T. Factorate - and this was only 2 and a half months after the Deputy Chief Medical Officer (Dr E. Harris, DCMO) had expressly stated that:

"all commercial Factor VIII imported into this country is also heat treated. There would thus appear to be no longer any need to use un-heat-treated Factor VIII concentrate." (August 1985).

Apart from the complete underestimation of the ongoing risk to spouses, by November 1985, there is hearsay evidence that even more haemophiliac patients are seroconverting to become anti-HTLV III positive despite having received heat-treated Factor VIII. Even as late as February 1986, we still have a new HIV infection in a UK haemophiliac caused by Armour batch A28306.

Source:
Type: DOH FOI Document - CMO Final Draft of Speech to PHLS on AIDS. 24 October 1985.
Location: UK
Find related entries
1986
circa 13 February
CMO - Donald Acheson - Patients Infected by Heat-Treated Factor 8
In a Guardian article of Tuesday, 15th April, 1986, we learn that 2 months earlier, Dr Donald Acheson, Chief Medical Officer, dismissed evidence of patients being infected by heat-treated Factor 8:

"Doctors in Amsterdam reported that a 27-year-old man had been infected after being given supplies of the blood clotting agent which had been heat-treated to kill the virus..."

"Senior Department of Health and Social Security officials were studying the report yesterday."

"Two months ago the Government's Chief Medical Officer, Dr Donald Acheson, dismissed evidence that Dutch patients had been infected by heat-treated Factor 8, and assured British haemophiliacs that US supplies were safe."

Legal Note: There was little question, in this case, of a clear causal relationship between the conduct of a US blood product manufacturer and the result of this commercial product on the patient - since the Amsterdam-based physicians had reported in the Lancet that their patient had been given exclusively heat-treated Factor VIII originating from the United States.

NOTE: There were grave consequences to the CMO's dismissal of the Dutch evidence. Only a week later, (on 21 February 1986) Armour batch A28306 is found to be the likely cause of HIV infection in a UK haemophiliac. By late September '86, Armour's H.T. Factorate is again reported to have led to seroconversions in another two haemophiliacs in the UK.

Source: Link #1
Type: Guardian Article - Aids threat remains in safe Factor 8. Tuesday, 15 April 1986.
Location: UK
Find related entries
1986
21 February
Dr Lawlor referring to Armour - Late Seroconversions
Armour batch A28306 is the likely cause of HIV infection in a UK haemophiliac on 21 February 1986.

(The Armour product was heat treated at 60 Centigrade for 30 hours and was made from plasma of untested donors. This product is associated with up to 12 cases of late seroconversion.)

Background: Only a week or so earlier, the Government's CMO, (Chief Medical Officer), Dr Donald Acheson, dismissed evidence that Dutch patients had been infected by heat-treated Factor 8, and assured British haemophiliacs that US supplies were safe.

NOTE: It should be noted that the Amsterdam-based physicians had reported in the Lancet that their patient had been given exclusively heat-treated Factor VIII originating from the United States.

Source: Additional Source:
Link #2
Type: Witness Evidence
Location: UK
Find related entries
1986
21 February
Dr Lawlor referring to Armour - Infection from Batch A28306
The untested plasma that Armour batch A28306 originates from was made into similar types of Armour product which infect haemophiliac boys in the Birmingham area.
Source: Lindsay Tribunal Report. Page 53
Type: Witness Evidence
Location: UK
Find related entries
1986
March
DHSS / Armour - Efficacy of Heat Treatment
DHSS questions Armour about the efficacy of its heat-treatment methods.

Departmental staff meet with Armour officials to review the data on inactivating viruses.

Source: Krever Commission Report (1997), Vol 3, Part IV, Chapter 33, page 933.
Type: Questioning / Meeting
Location: USA
Find related entries
1986
late September
Armour - H.T. Factorate Haemophiliac Seroconversions
Another 2 seroconversion cases are reported in persons with haemophilia in the UK who have been treated with Armour's H.T. Factorate.
Source: Krever Commission Report (1997), Vol 3, Part IV, Chap. 33, page 933.
Type: Development
Location: UK
Find related entries
1986
6 October
DHSS / Armour Voluntary H.T. Factorate Withdrawal
DHSS staff meet again with Armour officials. At this meeting, Armour agrees to voluntarily withdraw all H.T. Factorate from the U.K. market.

The company also agrees to relinquish its product licences for all factor VIII concentrate products.

Source: Krever Commission Report (1997), Vol 3, Part IV, Chapter 33, page 933.
Type: Meeting
Location: USA
Find related entries
1988
January
BTSB - Armour Voluntarily Withdraws Heat-Treated Factor VIII
Armour voluntarily withdraws heat-treated factor VIII which is suspected of causing seroconversion in Canadian hemophiliacs.
Source: Lindsay Tribunal Report. Page 56 (Witness Testimony of Dr. Lawlor of BTSB)
Type: Development (Witness Testimony)
Location: USA
Find related entries
1988
27 January
BTSB - Armour Pharmaceutical Seeks an Indemnity from BTSB
Armour Pharmaceutical seeks an indemnity from BTSB, under which Armour cannot be held responsible by BTSB from all third party liability in respect of HIV, Hepatitis or other viral infection arising from the sale or use of factor concentrate, including, settlement costs, judgements and attorney's fees. All Armour trademarks and company names are to be removed from products supplied to the BTSB. This request for an indemnity arose because there was a move in the U.S. away from dry heated treatment, towards high purity product. Armour did not want to manufacture two different products.

Note: However, Armour does in fact continue to fractionate for the BTSB for some time.

Source: Lindsay Tribunal Report. Pages 56-7
Type: Request for Indemnity
Location: USA
Find related entries
1988
17 February
BTSB Board Meeting - Armour Indemnity - Serious Implications
The request from Armour for an indemnity from BTSB is discussed at a BTSB Board Meeting. The CEO explains that this request has very serious implications for the Board. The production of factor VIII will cease on 31st December 1988, after which the Board will be faced with a choice of Monoclate or pasteurised product. Both products have implications on the goal of self-sufficiency.

Product Liability Acts are about to become law.

Source: Lindsay Tribunal Report. Page 57
Type: Meeting
Location: USA
Find related entries
Timeline Copyright ©2006 Andrew March & Haydn Lewis
All rights reserved

 

Telephone

07717471460

Follow

Address

7 Yessell Lane, Hinton-on-the-Green, Evesham, Worcestershire WR11 2RE

Terms & Conditions | Privacy | Website © Tainted Blood 2021